Abstract
The CAPITAL study, an open label, randomized phase III study in Japan, demonstrated carboplatin plus nab-paclitaxel significantly improved overall survival (OS) and progression-free survival (PFS) compared to docetaxel. We conducted this analysis to assess the extent to which dose and schedule modifications of carboplatin and nab-paclitaxel were necessary in elderly patients with squamous non-small cell lung cancer (NSCLC).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
